Zbtb33 Knockout cell line(RM-1)
Catalog Number: KO01142
Price: Online Inquiry
Catalog Number: KO01142
Price: Online Inquiry
| Product Information | |
|---|---|
| Product Name | Zbtb33 Knockout cell line(RM-1) | 
| specification | 1*10^6 | 
| Storage and transportation | Dry ice preservation/T25 live cell transportation. | 
| Cell morphology | fibrous,Adherent cells | 
| Passage ratio | 1:3~1:4 | 
| species | Mouse | 
| Gene | Zbtb33 | 
| Gene ID | 56805 | 
| Build method | Electric rotation method / virus method | 
| Mycoplasma testing | Negative | 
| Cultivation system | 90%RPMI-1640+10%FBS | 
| Parental Cell Line | RM-1 | 
| Quality Control | Genotype: Zbtb33 Knockout cell line(RM-1) >95% viability before freezing. All cells were tested and found to be free of bacterial, viruses,mycoplasma and other toxins. | 
| Gene Information | |
|---|---|
| Gene Official Full Name | zinc finger and BTB domain containing 33provided by MGI | 
| Also known as | Kaiso; Znf-kaiso; E130014G12Rik | 
| Gene Description | Predicted to enable DNA-binding transcription repressor activity, RNA polymerase II-specific; RNA polymerase II cis-regulatory region sequence-specific DNA binding activity; and methyl-CpG binding activity. Predicted to be involved in negative regulation of transcription by RNA polymerase II; regulation of cytokine production; and regulation of immune system process. Predicted to act upstream of or within DNA-templated transcription. Located in nucleus. Is expressed in several structures, including bladder; central nervous system; early conceptus; eye; and gonad. Orthologous to human ZBTB33 (zinc finger and BTB domain containing 33). [provided by Alliance of Genome Resources, Apr 2025] | 
| Expression | Ubiquitous expression in CNS E11.5 (RPKM 8.7), CNS E18 (RPKM 8.6) and 24 other tissues See more | 
We develop gene knockout solutions tailored to customer requirements and the condition of the target gene.
						    			Cas9 Protein
						    			Cas9 mRNA sgRNA
						    			Cas9 Plasmid
						    			Cas9 Virus
						    	A – Exon KO
gRNAs are designed in the introns flanking the exon, targeting non-multiple-of-3 base deletions in the exon, resulting in frameshift mutations.
B - Frameshift KO
gRNAs are designed within the exon, creating non-multiple-of-3 base deletions to induce frameshift mutations.
C - Complete KO
The entire gene coding sequence is deleted, achieving large-scale knockout effects.
						    	
						    		KO Strategy Design
						    		CRISPR Plasmid/Lentiviral Vector Construction
						    		Lentiviral Packaging
						    		Cell Transfection/Lentiviral Infection
						    		Drug Selection
						    		Cell Cryopreservation
						    		Quality Control
						    		Sequencing Validation
						    		Monoclonal Cell Line Generation
						    		Pool Efficiency Validation
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
| 
								 There is no product in your cart.  | 
						
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.